statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Plus Therapeutics will secure $3 million in funding from the Department of Defense for pediatric brain cancer trial expansion.
read more...

Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense

AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the Company ), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...

Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference

Plus' CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges CSF-01 testing is used as an...

Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic

Plus Therapeutics (PSTV Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Walsh from...

Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds

A total of 18 patients have been dosed in the trial to date Company anticipates moving into Cohort 6 in Q2 2024 following standard safety review AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE...

Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

Plus Therapeutics (PSTV Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy...

Buy Rating Affirmed for Plus Therapeutics Amid Strong Financials and Promising Clinical Trials

Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases (LM) Reached...

Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

AUSTIN, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the Company ), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...

Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Watchers	17,983
52-Wk Low	$0.9694
52-Wk High	$5.09

Volume	182,184.00
52-Wk High	$5.09
52-Wk Low	$0.9694

Period	Estimated	Reported	Surprise	Result
Q1'24	-$1.09	--	--	N/A
Q4'23	-$1.07	-$0.55	48.72%	BEAT
Q3'23	-$0.88	-$1.00	-14.07%	MISSED
Q2'23	-$1.73	-$0.59	65.83%	BEAT
Q1'23	-$2.06	-$2.10	-1.82%	MISSED

PSTV Plus Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals